Potential shared mechanisms in atopic dermatitis and type 2 diabetes identified via transcriptomic and machine...

Area of Science:

• Immunology
• Metabolic disorders
• Genomics

Background:

• Atopic dermatitis (AD) involves chronic skin inflammation and barrier dysfunction.
• Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia and systemic inflammation, worsening insulin resistance.
• Shared molecular mechanisms between AD and T2DM are largely unexplored.

Purpose of the Study:

• To investigate the common molecular mechanisms underlying atopic dermatitis and type 2 diabetes mellitus.
• To identify shared genes and pathways that could serve as diagnostic biomarkers or therapeutic targets.

Main Methods:

• Integration of transcriptomic data from AD and T2DM patients.
• Differential gene expression analysis (DEGs).
• Gene Set Variation Analysis (GSVA).
• Machine learning algorithms.
• Virtual screening for drug candidates.

Main Results:

• Identification of significantly upregulated genes, including LTF, LTB4R, and CCR1, common to both AD and T2DM.
• CCR1 identified as a potential key player in the shared pathophysiology.
• Virtual screening identified Dioscin, Camptothecin, and Albamycin as compounds with high affinity for CCR1.

Conclusions:

• This study reveals shared molecular underpinnings between atopic dermatitis and type 2 diabetes mellitus.
• LTF, LTB4R, and CCR1 are proposed as potential biomarkers for both diseases.
• Dioscin, Camptothecin, and Albamycin show promise as novel therapeutic agents targeting CCR1 for AD and T2DM treatment.